SCHEMBL4868121

SCHEMBL4868121

COc1cccc(CNc2ncnc3ccccc23)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
EGFR P00533 6/20 0.74
NR2F2 P24468 3/20 0.74
POLB P06746 1/20 0.74
HTT P42858 3/20 0.74
CLK4 Q9HAZ1 6/20 0.69
LMNA P02545 6/20 0.69
TSHR P16473 3/20 0.69
USP2 O75604 3/20 0.69
ALDH1A1 P00352 3/20 0.69
CYP1A2 P05177 3/20 0.69
CYP3A4 P08684 3/20 0.69
CYP2D6 P10635 3/20 0.69
CYP2C9 P11712 3/20 0.69
CYP2C19 P33261 3/20 0.69
HSD17B10 Q99714 3/20 0.69
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
HIF1A Q16665 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865169 0.90 EGFR (0.78) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL15923256 0.87 EGFR (0.70) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL3112115 0.85 EGFR (1.00) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL11251288 0.84 LMNA (0.60) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL15923150 0.83 SMN1; SMN2 (0.59) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL15922790 0.83 SMN1; SMN2 (0.59) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL25250055 0.83 EGFR (1.00) MAPK1SMN1; SMN2EGFRNR2F2POLB
SCHEMBL28119990 0.83 HTT (0.67) MAPK1SMN1; SMN2EGFRHTTCLK4
SCHEMBL6833333 0.82 EGFR (1.00) MAPK1SMN1; SMN2EGFRHTTCLK4
SCHEMBL4868010 0.82 APP (0.78) MAPK1SMN1; SMN2EGFRNR2F2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPK1 513/4885SMN1; SMN2 4818/4885EGFR 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.